October 13, 2021 | Highland, MD – The Jayne Koskinas Ted Giovanis Foundation for Health and Policy has extended prior JKTGF funded research to Heiko Enderling, Ph.D., a faculty member of Moffitt Cancer Center, to support his work personalizing radiation therapy to better fight breast cancer.
It is now widely recognized that breast cancer therapy should be tailored to individual patients. While patient-specific data has affected the decision for use of chemotherapy, it has yet to impact radiation therapy, the single most used therapeutic treatment in oncology.
This research seeks to decipher the architecture of the tumor-immune ecosystem in biopsy tissues to identify the optimal radiation protocol – on a per-patient basis – to induce robust immunity and eradicate the tumor.
“Radiation therapy is the most used therapy for fighting breast cancer, yet no clinical trials have attempted to individualize it,” said Ted Giovanis, founder and president of the JKTG Foundation.
“Heiko’s research has challenged current practice with exciting results, and the Foundation is pleased to further support his work so future breast cancer patients benefit from individualized treatment and better outcomes.”
There’s an old adage – them that can do – do. Them that can’t do – teach. Many institutions and academia generally rely on credentialed academicians equating credentials with mastery of a subject area.
Have you ever suggested firing yourself? It’s worth asking the question of yourself – particularly if you’re a healthcare leader today.
JKTG Founder and President Ted Giovanis, leading researchers, and University leaders gathered at the Johns Hopkins Welch Medical Library this week to formally mark the dedication of the Giovanis Institute for Translational Cell Biology – a symbolic first step of this important cancer research program.